RxDoctor Payments Data

Joseph Lumia, PA

Physician Assistant · Oneida, NYNPI 1528541018

Payments from drug & device makers

$2,310in general payments, 2019–2025

Across 89 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$711
  • AbbVie$278
  • GSK$174
  • Biohaven Pharmaceutical Holding Company Ltd.$164
  • Novartis$155
  • Boehringer Ingelheim$125
  • plus $703 from 19 others

What the payments were for

  • Food & beverage$2,310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,310 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$27,558
Medicare patients
181
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,503
FarxigaDapagliflozin Propanediol14$13,952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,283
Albuterol Sulfate HfaAlbuterol Sulfate40$1,175
Atorvastatin Calcium114$1,166
Omeprazole43$605
Metformin Hcl ErMetformin Hcl25$579
Levothyroxine Sodium48$514
Metoprolol Succinate29$487
Rosuvastatin Calcium24$482
Lisinopril51$360
Losartan Potassium22$296
Simvastatin30$280
Gabapentin15$276
Amlodipine Besylate33$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$174$18,50322 claims
AstraZenecaFarxiga$711$13,95214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Oneida

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →